HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

885.887

+7.0980.81%

Number of Gainers:11

Number of Losers:3

Number of Flat:3

PE:- -

High:888.258

Open:876.263

Low:869.207

Close:878.789

Volume:111.68M

Turnover:925.83M

Market Cap:598.87B

Float Cap:495.86B

Loading ...

Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS

Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626

THOMSON REUTERS

Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication

UOB Kay Hian Downgrades Ping An Healthcare and Technology to Hold from Buy; Price Target is HK$6.70

MT Newswires Live

Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?

CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors

BYD Electronic (International) Stock Slips 5.1% in Hong Kong

Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy

Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026

Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum

Market Bets on BOJ Rate Hike While CICC's Merger Wins Regulatory Approval

Major Shift in Sell-Side Research: Healthcare Analyst Switches to Semiconductors

CSPC Pharma Begins Phase II Study of Influenza Drug in China

MT Newswires Live

Fourth Breakthrough Therapy Designation Granted to EGFR-Targeted ADC Developed by CSPC

CSPC Pharma Initiates Phase II Trial of SYH2085 Tablet for Uncomplicated Influenza in Chinese Adults

Jinan Pingjia's 60% Stake Relisted at 24 Million Yuan After Once Being Valued at 154 Million

Sino Biopharma Reports Phase I Data Showing Tqc3721 Dry Powder Inhaler Boosts COPD Lung Function in Dose-Ranging Trial

Fosun Pharma Spends HK$1.18M on Share Buyback on September 7

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1515/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":885.8868,"timestamp":1789356440800,"preClose":878.7892,"halted":0,"volume":111675634,"delay":0,"changeRate":0.008077,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":7.097595,"latestTime":"09-14 11:27:22","open":876.263,"high":888.2582,"low":869.2073,"amount":925826612,"amplitude":0.021679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789358400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.00153,"increases":11,"decrements":3,"flats":3,"marketCap":598866237376,"floatMarketCap":495858983104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":888.2582,"amplitude":0.021679,"preClose":878.7892,"low":869.2073,"pbRate":"1.318473","latestPrice":885.8868,"volume":111675634,"delay":0,"open":876.263,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":942.123,"twentyDayClose":915.795,"sixtyDayClose":842.862,"secType":"PLATE","market":"HK","turnoverRate":0.00153,"peRate":17.086203,"marketCap":598866237376,"floatMarketCap":495858983104,"timestamp":1789356440800,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":11,"down":3,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665291593","title":"Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528","url":"https://stock-news.laohu8.com/highlight/detail?id=2665291593","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665291593?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861070,"startTime":"0","endTime":"0","summary":"Sino Biopharm presents ERS 2026 preclinical data for oral STAT6 degrader TQH5528Sino Biopharmaceutical disclosed preclinical data for TQH5528, an oral STAT6 degrader, already presented at ERS 2026.Stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLb1BcpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329613","title":"CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329613","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329613?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860844,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2083 dry eye dropsCSPC received China NMPA clearance to start clinical trials of SYH2083 eye drops, a small-molecule novel drug.Initial indication target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4D1fT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","LU0326950275.SGD","BK1521","LU1226288170.HKD","LU1993786604.SGD","LU0315179316.USD","IE00BZ08YS42.EUR","LU1226288253.USD","LU1152091754.HKD","SG9999004220.SGD","KURE","IE0008368742.USD","BK1515","LU0072913022.USD","LU1328277881.USD","LU0067412154.USD","LU1951186391.HKD","LU0314109678.HKD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1008478684.HKD","BK1191","HK0000165453.HKD","LU1152091168.USD","IE0008369823.USD","IE00BZ08YT58.USD","01093","LU0501845795.SGD","LU0880133367.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2039709279.SGD","LU1960683339.HKD","LU0140636845.USD","LU1226287792.SGD","LU1813983027.USD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329660","title":"CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329660?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:47","pubTimestamp":1788860822,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1807302812.USD","LU1226288253.USD","IE00B031HY20.USD","LU0501845795.SGD","LU1008478684.HKD","LU2039709279.SGD","LU0067412154.USD","IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","KURE","LU0140636845.USD","LU1226288170.HKD","LU1813983027.USD","IE0008369823.USD","01093","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0880133367.SGD","BK1515","HK0000165453.HKD","LU1328277881.USD","BK1191","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1226287792.SGD","LU1951186391.HKD","IE00B543WZ88.USD","IE0008368742.USD","BK1521","LU1993786604.SGD","LU0326950275.SGD","LU1226287875.USD","LU0315179316.USD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932955","title":"Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932955?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:44","pubTimestamp":1788860689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0028","BK0183","BK0096","BK0175","BK0196","BK0188","BK1191","BK1593","BK0012","02196","BK0187","BK0239","BK1515","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132147233","title":"Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1132147233","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132147233?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:20","pubTimestamp":1788859248,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SH: 600196) has announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","PSYK","IBBJ","BK0028","BK0175","IBBQ","BK0060","02196","BK0196","BMED","BK1593","MDTX","BK1191","BK0239","BK0187","BK0096","600196","BK1515","BK0183","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332699","title":"UOB Kay Hian Downgrades Ping An Healthcare and Technology to Hold from Buy; Price Target is HK$6.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332699","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332699?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858965,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology (HKG:1833) has an average rating of overweight and mean price target of HK$9.41, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and ec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1571","BK1142","BK1615","01833","BK1247","BK1219","BK1515","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150107003","title":"Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150107003","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150107003?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:48","pubTimestamp":1788857312,"startTime":"0","endTime":"0","summary":"On the morning of September 7, KINTOR PHARMA-B (09939) announced that its human long-term safety trial for KT-939, a novel and highly effective tyrosinase inhibitor developed in-house to suppress...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325339","title":"CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325339","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325339?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:32","pubTimestamp":1788856320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 2.7% to 9.42 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25317.18.This was the stock's second consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 19% short of its 52-week high of HK$11.63, which the company reached Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 6.9%, SSY Group Ltd. fell 0.9%, and United Laboratories International Holdings Ltd. rose 0.5%.Trading volume totaled 71.8 million shares, compared to the 50-day average of 105.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE0008368742.USD","BK1521","LU1960683339.HKD","LU0315179316.USD","LU0880133367.SGD","01093","HK0000165453.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0072913022.USD","IE0008369823.USD","LU1226288253.USD","KURE","LU1993786604.SGD","LU2039709279.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU0140636845.USD","LU0067412154.USD","LU0501845795.SGD","LU1226288170.HKD","BK1515","IE00B5MMRT66.SGD","SG9999004220.SGD","LU1328277881.USD","LU1152091754.HKD","LU1807302812.USD","IE00B543WZ88.USD","LU1226287875.USD","LU1813983027.USD","LU1226287529.USD","LU1008478684.HKD","LU1152091168.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325355","title":"BYD Electronic (International) Stock Slips 5.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325355?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:31","pubTimestamp":1788856260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. shed 5.1% to 25.52 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25317.18.The stock's fall snapped a two-day winning streak.BYD Electronic  Co. Ltd. closed 43% below its 52-week high of HK$44.60, which the company achieved Oct. 2.The stock underperformed when compared to some of its competitors, as Times Universal Group Holdings Ltd. remained unchanged.Trading volume totaled 12.3 million shares, compared to the 50-day average of 12.6 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1540","BK1589","LU0274383008.USD","BK1504","BK1580","BK1607","BK1582","LU0348767384.USD","BK1167","BK1149","LU0348766576.USD","00285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341408","title":"Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341408?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:51","pubTimestamp":1788839513,"startTime":"0","endTime":"0","summary":"Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategySino Biopharmaceutical CEO Eric Tse told the Yabuli Forum on Sept. 5 it is pursuing counter-cyclical growth t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL2RNzg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","LU0882574055.USD","LU0640478417.SGD","LU0963555726.SGD","IE00BFTCPJ56.SGD","LU0128525929.USD","LU1863844749.USD","LU2293690082.USD","LU2133065610.SGD","03165","AZN.UK","LU0052756011.USD","LU0128525689.USD","LU1863844665.USD","LU0738911758.USD","LU0827474353.SGD","BK5011","LU0211328371.USD","LU0784385840.USD","LU0889566641.SGD","LU0960981461.USD","IE00BZ08YS42.EUR","LU1267930813.SGD","LU0211326755.USD","LU0047473722.SGD","LU1119994496.HKD","LU2091194634.USD","LU1051770623.HKD","LU2433249047.HKD","HK0000165453.HKD","LU1323610961.USD","LU0158827948.USD","LU0011850046.USD","LU0029864427.USD","LU2279689827.SGD","BK1515","LU0887340254.USD","LU1196032939.SGD","LU2125909247.SGD","LU0949170426.SGD","LU1153585028.USD","LU0345777659.USD","LU1019632923.USD","LU1355424745.HKD","LU0969580561.USD","LU0211327993.USD","LU2237443978.SGD","LU0972486137.USD","LU0077335932.USD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184154136","title":"Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1184154136","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184154136?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:50","pubTimestamp":1788835817,"startTime":"0","endTime":"0","summary":"Shares of SBP GROUP (01177) advanced nearly 3% in Hong Kong trading, last up 2.74% at HK$5.62 with turnover reaching HK$111 million.On September 7, the company announced that its subsidiary, Chia Tai...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1515","BK4585","IE00BZ08YR35.GBP","BK1191","BK4588","IE00BZ08YT58.USD","BK1521","KCAI","IE00BZ08YS42.EUR","01177","VXUS","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183000307","title":"Hong Kong Stock Market Alert | ALEBUND-B (09637) Surges Over 6% on Stock Connect Inclusion and Index Membership, Mircera Sales Jump Approximately 105% Boosting Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1183000307","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183000307?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:22","pubTimestamp":1788834140,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares climbed more than 6% in Monday's session, trading up 6.02% at HK$28.52 as of the time of writing. The stock recorded a turnover of HK$6.452 million with a volume ratio of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1161","BK4585","09637","09939","HSCI","BK1574","KCAI","BK1515","BK1191","FLHK","159938","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161695676","title":"Market Bets on BOJ Rate Hike While CICC's Merger Wins Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1161695676","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161695676?lang=en_us&edition=fundamental","pubTime":"2026-09-08 07:46","pubTimestamp":1788824797,"startTime":"0","endTime":"0","summary":"The National Copyright Administration has issued the \"15th Five-Year Plan for Copyright Work,\" outlining key targets through 2030. The plan sets a national work registration target of 9.5 million...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IJUL","IE0008368742.USD","FNDF","BK1149","FDEV","HJPX","LU1328277881.USD","NISM","EFAS","BK1564","LU1951186391.HKD","HDEF","DMRI","FDT","BK0276","HSCZ","BK1516","FIDI","LU1580142542.USD","EFAD","IE00BZ08YR35.GBP","MTRA","LU2039709279.SGD","EFAV","NTSI","BK1501","CVIE","JHMD","PIEQ","LU1508157978.USD","BK1122","BCIL","LU1781817850.SGD","EXUS","LU1226288170.HKD","LU1152091168.USD","IAUG","BK1191","PCIG","AVDE","IHDG","09976","KURE","GAID","IBUF","IAGG","LU0880133367.SGD","LU0501845795.SGD","PDN","IE00B031HY20.USD","BK1193","IQDG","LU0067412154.USD","LU1655091616.SGD","HDMV","WCMI","OSEA","IE00B543WZ88.USD","BK1533","DFGX","BK4585","VXUS","LU0140636845.USD","LU0359201612.USD","IJAN","IDHD","IE0008369823.USD","01093","JIDE","DFIV","IDVY","DWM","IDYN","IE00BZ08YT58.USD","LU1152091754.HKD","RFDI","IE00B5MMRT66.SGD","PDEV","BBIN","QLVD","DIVI","BK1147","LU0326950275.SGD","PJIO","LU0314109678.HKD","DBAW","LU1023057109.AUD","LU0072913022.USD","LU1226288253.USD","IDLV","AFDM","IQLT","IDLB","AVIV","OAKI","GWX","LU1226287875.USD","601995","DFAI","DIHP","03908","YDEC","FEOE","EFV","FNDC","KCAI","LU1255011170.USD","SG9999002828.SGD","VDV","IFEB","LU0315179316.USD","NIHI","LU1226287529.USD","03308","RINT","IBFR","LU2663582299.SGD","LU1813983027.USD","IE00BZ08YS42.EUR","VIGI","LU0359202008.SGD","BK1249","LU1008478684.HKD","09678","BUFI","BK1515","EPIN","BK1109","HK0000165453.HKD","LU1226287792.SGD","LU0359201885.HKD","TLTD","UIVM","SG9999004220.SGD","IQSI","IFLO","DNL","LU1807302812.USD","IVSX","LU1960683339.HKD","DISV","YJUN","JDVI","IDHQ","BK4588","CGXU","LU1993786604.SGD","REFA","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169256250","title":"Major Shift in Sell-Side Research: Healthcare Analyst Switches to Semiconductors","url":"https://stock-news.laohu8.com/highlight/detail?id=1169256250","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169256250?lang=en_us&edition=fundamental","pubTime":"2026-09-07 22:10","pubTimestamp":1788790245,"startTime":"0","endTime":"0","summary":"Sell-side research has witnessed a notable career pivot as a healthcare-focused analyst has transitioned to covering the electronics sector, marking a significant departure from their academic and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1574","KCE","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665142623","title":"CSPC Pharma Begins Phase II Study of Influenza Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2665142623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665142623?lang=en_us&edition=fundamental","pubTime":"2026-09-07 21:11","pubTimestamp":1788786661,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) began a phase II clinical trial of SYH2085 tablets in China.The drug was developed by the company to treat uncomplicated influenza in adults, according to a Monday bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0326950275.SGD","LU1152091754.HKD","IE0008368742.USD","IE00B031HY20.USD","LU1807302812.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1993786604.SGD","BK1515","BK1191","LU1226287792.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0072913022.USD","LU1152091168.USD","01093","IE0008369823.USD","LU1226287875.USD","LU0314109678.HKD","LU1960683339.HKD","LU1226287529.USD","SG9999004220.SGD","LU0067412154.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1008478684.HKD","BK1521","LU1226288170.HKD","LU0140636845.USD","KURE","LU2039709279.SGD","LU1226288253.USD","LU1328277881.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU0315179316.USD","LU0501845795.SGD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111207955","title":"Fourth Breakthrough Therapy Designation Granted to EGFR-Targeted ADC Developed by CSPC","url":"https://stock-news.laohu8.com/highlight/detail?id=1111207955","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111207955?lang=en_us&edition=fundamental","pubTime":"2026-09-07 21:01","pubTimestamp":1788786078,"startTime":"0","endTime":"0","summary":"On September 7th, the CDE website revealed that SYS6010, developed by CSPC PHARMA, has been proposed for inclusion in the breakthrough therapy designation program. This designation is intended for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","HK0000165453.HKD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","LU1960683339.HKD","LU1152091168.USD","LU0314109678.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008368742.USD","LU0072913022.USD","BK1521","IE0008369823.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU0315179316.USD","LU1328277881.USD","LU1226288253.USD","IE00BZ08YS42.EUR","01093","LU1008478684.HKD","LU0880133367.SGD","BK1515","LU1813983027.USD","LU1993786604.SGD","BK1191","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0326950275.SGD","LU0140636845.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199113939","title":"CSPC Pharma Initiates Phase II Trial of SYH2085 Tablet for Uncomplicated Influenza in Chinese Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=1199113939","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199113939?lang=en_us&edition=fundamental","pubTime":"2026-09-07 19:36","pubTimestamp":1788780985,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced that the Phase II clinical trial of its SYH2085 tablet, designed for the treatment of uncomplicated influenza in adults, has formally commenced at the first clinical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","IE00BZ08YT58.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1226287875.USD","LU1226288170.HKD","01093","LU0314109678.HKD","LU0880133367.SGD","LU0067412154.USD","LU1993786604.SGD","LU0140636845.USD","LU1226288253.USD","BMED","BK1515","LU1152091168.USD","LU1807302812.USD","LU1008478684.HKD","LU1813983027.USD","LU0501845795.SGD","LU0326950275.SGD","PSYK","LU1960683339.HKD","IBBJ","IE00B5MMRT66.SGD","KURE","LU0072913022.USD","IE00B543WZ88.USD","MDTX","IBBQ","LU0315179316.USD","LU1152091754.HKD","LU1951186391.HKD","SG9999004220.SGD","BK1191","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","LU2039709279.SGD","LU1226287529.USD","LU1328277881.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135498525","title":"Jinan Pingjia's 60% Stake Relisted at 24 Million Yuan After Once Being Valued at 154 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1135498525","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135498525?lang=en_us&edition=fundamental","pubTime":"2026-09-07 19:21","pubTimestamp":1788780087,"startTime":"0","endTime":"0","summary":"More than two years have passed since the failed acquisition, and the 60% equity stake in Jinan Pingjia is once again on the property rights trading market, now with a minimum listing price of 24...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK0209","09939","BK1574","BK1515","301017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665163383","title":"Sino Biopharma Reports Phase I Data Showing Tqc3721 Dry Powder Inhaler Boosts COPD Lung Function in Dose-Ranging Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665163383","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665163383?lang=en_us&edition=fundamental","pubTime":"2026-09-07 18:36","pubTimestamp":1788777372,"startTime":"0","endTime":"0","summary":"Sino Biopharma reports Phase I data showing TQC3721 dry powder inhaler boosts COPD lung function in dose-ranging trialSino Biopharmaceutical reported Phase I data for its inhaled COPD drug candidate T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nNDL6f08vl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1515","BK1589","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1191","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146341626","title":"Fosun Pharma Spends HK$1.18M on Share Buyback on September 7","url":"https://stock-news.laohu8.com/highlight/detail?id=1146341626","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146341626?lang=en_us&edition=fundamental","pubTime":"2026-09-07 18:02","pubTimestamp":1788775333,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (HK: 02196) has announced a share repurchase transaction executed on September 7, 2026. According to the company's official disclosure, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0028","BK0183","BK0196","BK0060","BK0239","BK1191","BK0175","BK1515","BK1593","BK0012","BK0096","BK0188","02196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":179,"code":"91000000","status":"200"}]}}